#South Korea #Seoul #Probiotics #LISCure #JointWorks

LISCure BioSciences Achieves Landmark Approval

LISCure BioSciences, a leading innovator in the field of probiotics, has recently announced a momentous breakthrough: their proprietary joint health probiotic, JointWorks®, has been officially approved as a Recognized Health Functional Ingredient by the South Korean Ministry of Food and Drug Safety (MFDS). This approval not only marks a significant achievement for the company but also establishes JointWorks® as the world’s first clinically validated probiotic specifically tailored for joint health.

JointWorks® sets a unique precedent in the supplement landscape, focusing on the well-being of joints rather than relying solely on traditional natural extracts. It has consistently outperformed expectations, evidenced by robust results from a controlled, 12-week clinical study. Participants in the trial exhibited statistically significant improvements in multiple metrics related to joint health, including:

• - Total WOMAC Score: This index measures pain, stiffness, and physical functioning, showcasing marked improvements.
• - Visual Analogue Scale (VAS): Participants reported reduced pain levels, indicating enhanced daily functionality.
• - Quality of Life Assessment (EQ-5D-5L): Improvements in overall well-being were noted, reflecting the broader impact of joint health on life quality.
• - Inflammatory Cytokines: JointWorks® demonstrated a capacity to reduce these markers, which are associated with pain and joint dysfunction, further validating its effectiveness.

A New Era in Joint Health Solutions

The approval of JointWorks® signifies a paradigm shift in the realm of joint health solutions. As the health supplement market in Korea, valued at approximately KRW 480 billion (around USD 350 million), continually expands, the rising demographic of health-conscious, active seniors fuels the demand for science-backed supportive options. LISCure's innovative approach is poised to meet this growing consumer need with products that showcase both efficacy and safety.

Jae-Seok Shim, Vice President of LISCure, expressed enthusiasm over this recent approval, emphasizing its broader implications: "This marks not just functional validation but an exciting expansion of probiotics into joint health. It reinforces our commitment to pioneering the next generation of probiotics that extend beyond gut health, targeting systemic benefits including joint, kidney, cognitive, and metabolic health."

Recognition in the Scientific Community

The scientific foundation behind JointWorks® is robust, supported by numerous publications in esteemed peer-reviewed journals. Data regarding its mechanisms of action, including how it protects joint and cartilage health, suppresses inflammation, reduces pain, and preserves cartilage cells, have been made publicly accessible to enhance credibility and consumer trust.

Future Goals and Developments

Following this achievement, LISCure is looking forward to showcasing JointWorks® alongside Mobiome®, their hair health probiotic, at the upcoming SupplySide Global 2025 exhibition in Las Vegas—one of the most significant gatherings for food ingredients worldwide. This presentation underscores the company's commitment to expanding its innovative portfolio that addresses various health concerns, including kidney health, weight management, and blood sugar regulation.

In conjunction with their nutraceutical endeavors, LISCure remains focused on advancing its biopharmaceutical research pipeline. This includes progressing with the clinical trials for treatments targeting liver disease and anti-cancer interventions, which have already shown promise in preclinical studies.

Overall, LISCure BioSciences is not only setting itself apart in the probiotics market with its groundbreaking joint health product but is also actively working towards balancing innovative drug development alongside its growing nutraceutical segment, aiming for sustainable growth well into the future.

Conclusion

LISCure's journey marks a significant moment in the evolution of health supplements, particularly with joint health. The approval for JointWorks® showcases the potential for probiotics to address unmet health needs, and with ongoing research and development, the company is well-positioned to lead this category forward, benefitting countless individuals looking for effective ways to maintain their joint wellbeing.

With continuous evidence-based research and global collaborations, LISCure is poised to advance significantly in the health industry, promising a healthier future for its consumers.